Targazyme, Inc.

Targazyme, Inc. is a late-stage biopharmaceutical company developing breakthrough “point-of-care” products to improve clinical efficacy and safety in stem cell transplantation, immunotherapy for cancer, regenerative medicine, and gene therapy.

The company’s proprietary ex vivo enzymatic glyco-engineering platform, fucosylation, improves the therapeutic efficacy of cells by directing the fucosylated cells to the sites of disease and inflammation where higher retention leads to a superior therapeutic benefit.

Targazyme’s technology is broadly applicable to a range of therapeutic cells (natural or genetically-engineered), and as such, Targazyme’s product development strategy has focused on applying our technology to both established cell therapies such as hematopoietic stem cell transplantation, and emerging therapies, such as cancer cell-based immunotherapies, for which safety is a major obstacle and efficacy in solid tumors remains to be established.